Targeting lupus nephritis could be a more straightforward path to market for new lupus drugs – or at least that is what some drug makers are hoping. Lupus nephritis effects a smaller subset of patients than the more common systemic lupus erythematosus (SLE) and it could have some advantages when it comes to drug development: diagnosis is done by a test, the clinical endpoints are well defined, the condition can be life-threatening, and there are no approved treatments.
Given the high hurdle to developing new drugs for lupus and the high rate of clinical trial failures in the field, some drug makers like Aurinia Pharmaceuticals Inc
Deep Dive Into Lupus
This is the final piece in Scrip's series on the lupus market and pipeline. For more information, see:
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?